Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

A Stanford Medicine trial has shown success with CAR-T cell therapy in shrinking deadly childhood brain tumors. For one ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy arena. The therapy was cleared to treat relapsed or ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all ...

FDA approval of tarlatamab (Imdelltra) for small-cell lung cancer offers another example of progress. The novel bispecific ...

Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its chimeric antigen receptor (CAR)-T cell therapy for adult patients with ...